(MENAFN) Danish pharmaceutical company Novo Nordisk said it posted an increase of 10 percent in its operating profit and 5 percent rise of net profit in 2014, Xinhua reported.
The firm's operating profits reached USD5.25 billion, up from USD4.78 billion registered in 2013, while net profit hit USD4.02 billion, surging from USD3.82 billion in the previous year.
In the total, the firm's sales grew 6 percent on-year to USD13.48 billion, while sales of its flagship diabetes drug Victoza increased by 15 percent, hitting USD2.03 billion last year.
Sales growth for 2015 is forecasted around 12 percent, while operating profit growth is expected to be near 10 percent this year. Novo Nordisk predicts a net loss of around USD759.25 million in 2015.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.